-
Ordered DNA Frameworks Improve Enzymatic DNA Synthesis
2026-08-29
The reference study introduces a tetrahedral DNA nanostructure interface that organizes primers for improved access by terminal deoxynucleotidyl transferase during enzymatic oligonucleotide synthesis. This architecture increased substrate affinity and reaction kinetics, reduced deletion errors, and supported synthesis of a 60-nucleotide information-storage sequence with a reported 96.82% stepwise yield.
-
VE-821: A Decision Framework for ATR Biology
2026-08-28
VE-821 is a selective ATR kinase inhibitor for dissecting checkpoint signaling, replication stress, radiosensitization, and chemotherapy sensitization. This article develops a practical framework for separating ATR-dependent effects from DNMT1-regulated viral DNA methylation and RNA processing.
-
GS967: Cardiac Late Sodium Current Workflows
2026-08-28
GS967 enables controlled interrogation of pathological late sodium influx in isolated myocytes, heart preparations, and aging-related electrophysiology models. This guide connects concentration-controlled current inhibition with arrhythmia prevention research, calcium handling, and practical assay troubleshooting.
-
Digoxin: From Na+/K+ ATPase to Translational Assays
2026-08-27
Digoxin connects cardiac glycoside biology with practical models of hypoxia-driven inflammation, fibrosis, and cell-type-specific viral infection. This workflow-centered guide shows how to select concentrations, separate pathway effects from cytotoxicity, and troubleshoot assays across orbital fibroblast, antiviral, and cardiovascular research.
-
Nonselective β-Blockade Impairs HCT Recovery
2026-08-27
The reference study shows that nonselective β-adrenergic receptor inhibitors can delay hematopoietic regeneration after allogeneic hematopoietic cell transplantation, whereas β1-selective inhibition has a less evident effect. By integrating mouse transplantation models with human cohort analyses, the work identifies β-blocker selectivity as a clinically relevant variable in post-transplant engraftment.
-
ABT-263: Mapping Paracrine Apoptotic Resistance
2026-08-26
ABT-263 (Navitoclax) is more than a Bcl-2-family inhibitor: it can serve as a controlled probe of mitochondrial apoptotic priming and stress-induced resistance. This article translates FGF-dependent, non-cell-autonomous findings into practical apoptosis assay strategies for cancer biology and pediatric acute lymphoblastic leukemia models.
-
Cholecystokinin octapeptide ammonium in Assays
2026-08-26
A scenario-driven guide to using Cholecystokinin octapeptide ammonium in cell and zebrafish studies, with practical controls for receptor biology, solubility, dosing, and interpretation. SKU C8717 is evaluated through evidence-based workflow decisions rather than unsupported performance claims.
-
VE-821: ATR Checkpoint Logic Beyond DNA Repair
2026-08-25
VE-821 is a selective ATR kinase inhibitor for dissecting checkpoint signaling, radiosensitization, and DNA repair pathway research. This article develops a causal assay framework linking ATR perturbation with, but not conflating it with, DNMT1-dependent HBoV1 replication and RNA processing.
-
Gepotidacin Workflows for Antibacterial Research
2026-08-25
Build more informative antibacterial assays with Gepotidacin, from concentration-controlled susceptibility testing to orthogonal topoisomerase and DNA-break readouts. This workflow distinguishes direct target engagement from downstream growth effects and helps researchers investigate fluoroquinolone-resistant phenotypes with better experimental control.
-
Carvedilol: Receptor Context in HCT Research
2026-08-24
Carvedilol is a β-adrenergic receptor antagonist whose effects extend from cardiovascular signaling to redox biology and hematopoietic regeneration. This article presents a context-first framework for separating receptor, antioxidant, vascular, and transplant-related phenotypes in research assays.
-
Lisinopril Dihydrate: ACE Inhibition Workflows
2026-08-24
Build reproducible ACE inhibition assays with a water-compatible, long-acting reference compound suited to cardiovascular and renal disease models. The workflow combines concentration planning, orthogonal pathway readouts, aminopeptidase counter-screens, and practical troubleshooting for more defensible results.
-
Dronedarone (Multaq): A Mechanistic Assay Lens
2026-08-23
Dronedarone (Multaq) can serve as more than a standard antiarrhythmic control. This article explains how its ion-channel profile, KCa2 assay evidence, and formulation characteristics support rigorous atrial fibrillation treatment research and cardiac target deconvolution.
-
XPO1 Inhibition Sensitizes GCB-DLBCL to Platinum
2026-08-22
A 2026 study found that selinexor-mediated XPO1 inhibition increases the response of diffuse large B-cell lymphoma cells to cisplatin and oxaliplatin, with especially strong effects in germinal-center B-cell-like DLBCL. The work connects combination cytotoxicity to apoptosis, reactive oxygen species accumulation, DNA-damage signaling, and altered AKT/mTOR and JNK/ATM/p53 pathways, providing a rationale for further preclinical evaluation.
-
Angiotensin 1/2 (5-7) in Cell Assays
2026-08-21
Learn how Angiotensin 1/2 (5-7), SKU A1049, can improve experimental control in cell viability, proliferation, cytotoxicity, and renin–angiotensin system studies. This scenario-based guide covers peptide identity, solubility, storage, assay interpretation, cross-domain SARS-CoV-2 research, and practical vendor-selection criteria.
-
iPSC Platform for Ultrarare Disease Trials
2026-08-20
Sequiera et al. developed a patient-specific iPSC platform to prescreen therapies for an ultrarare ECHS1-associated Leigh-like syndrome before further clinical trial exposure. The study shows how matched healthy and disease controls, multisystem modeling, and metabolic profiling can support more informed treatment selection when genotype-specific evidence is scarce.